Welcome to our dedicated page for Neumora Therapeutics SEC filings (Ticker: NMRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Neumora Therapeutics, Inc. filings document the regulatory record for a Nasdaq-listed clinical-stage biopharmaceutical company developing therapies that target novel mechanisms of action. The company’s 8-K reports furnish financial results, business updates, corporate presentations, and clinical-development disclosures for programs including navacaprant, NMRA-511, NMRA-898, NMRA-861, and NMRA-215.
Neumora’s SEC filings also cover proxy governance, executive compensation, board and shareholder voting matters, registered common stock, and capital-structure events. Recent disclosure areas include Regulation FD presentations, unregistered equity issuance tied to a loan conversion right, and formal exhibits that describe program plans, financing arrangements, risk statements, and public-company reporting obligations.
Neumora Therapeutics disclosed that K2 HealthVentures Equity Trust LLC and two managing members, Parag Shah and Anup Arora, report beneficial ownership tied to convertible debt that can be converted into Common Stock. Under a loan and security agreement, K2HV Equity has the right to convert up to $10,000,000 of principal into Conversion Shares at the lesser of $0.8774 per share or the lowest effective price in the Issuer's next equity financing; the filers assumed the $0.8774 conversion price.
As a result, the Reporting Persons disclose beneficial ownership of 11,397,310 shares, representing approximately 6.6% of Common Stock on a converted basis. The Schedule shows shared voting and dispositive power over those shares (no sole voting or dispositive power). The reporting address for the filers is provided as 855 Boylston Street, Boston, MA.